This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Patient Satisfaction and Quality of Life Impact - PecFent® (Qualipec)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by Archimedes Development Ltd.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Archimedes Development Ltd Identifier:
First received: October 1, 2012
Last updated: July 10, 2013
Last verified: July 2013

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.

• Study objectives include assessment of early treatment satisfaction.

Condition Intervention
Breakthrough Cancer Pain Drug: PecFent® (fentanyl) nasal spray

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Spanish , Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)

Resource links provided by NLM:

Further study details as provided by Archimedes Development Ltd:

Primary Outcome Measures:
  • Satisfaction [ Time Frame: Satisfaction will be assessed approximately 1 hour after each breakthrough pain (BTPc) episode treated with PecFent® from completion of titration through Day 7 ]
    Satisfaction will be assessed using a 4-point Likert scale.

Estimated Enrollment: 150
Study Start Date: September 2012
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
PecFent® Drug: PecFent® (fentanyl) nasal spray


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Cancer patients with breakthrough pain

Inclusion Criteria:

  • Adult (aged ≥18 years) with cancer
  • Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01698645

Contact: Yolanda Riesgo, MD + 34 913510373

Hospital 12 de Octubre Recruiting
Madrid, Spain, 28041
Contact: Hernan Cortes, MD    + 34 913 908 349   
Principal Investigator: Hernan Cortes, MD         
Sponsors and Collaborators
Archimedes Development Ltd
  More Information

Responsible Party: Archimedes Development Ltd Identifier: NCT01698645     History of Changes
Other Study ID Numbers: CP070/12
Study First Received: October 1, 2012
Last Updated: July 10, 2013

Keywords provided by Archimedes Development Ltd:
quality of life
breakthrough cancer pain

Additional relevant MeSH terms:
Breakthrough Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anesthetics processed this record on August 23, 2017